Noncollagenous 16A domain of type XVII collagen-reactive CD4 + T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model

Clinical Immunology

Volumn 142, Issue 2, 2012, Pages 167-175

  Ujiie, Hideyuki ^a   Shibaki, Akihiko ^a   Nishie, Wataru ^a   Shinkuma, Satoru ^a   Moriuchi, Reine ^a   Qiao, Hongjiang ^a   Shimizu, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoimmune disease; ; Autoreactive T cells; ; CD40 ligand; ; Pathomechanism

Indexed keywords

COLLAGEN ANTIBODY; COLLAGEN TYPE 17; COLLAGEN TYPE 17 ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BULLOUS PEMPHIGOID; CD4+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; DISEASE COURSE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL; SKIN DEFECT; SPLEEN CELL;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BULLOUS; TIME FACTORS;

EID: 84856522358     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.10.002     Document Type: Article

References (37)

1. Diaz L.A., Ratrie H., Saunders W.S., Futamura S., Squiquera H.L., Anhalt G.J., et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J. Clin. Invest. 1990, 86:1088-1094.
2. Giudice G.J., Emery D.J., Diaz L.A. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J. Invest. Dermatol. 1992, 99:243-250.
3. Hopkinson S.B., Riddelle K.S., Jones J.C. Cytoplasmic domain of the 180-kD bullous pemphigoid antigen, a hemidesmosomal component: molecular and cell biologic characterization. J. Invest. Dermatol. 1992, 99:264-270.
4. Ishiko A., Shimizu H., Kikuchi A., Ebihara T., Hashimoto T., Nishikawa T. Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin. J. Clin. Invest. 1993, 91:1608-1615.
5. Bedane C., McMillan J.R., Balding S.D., Bernard P., Prost C., Bonnetblanc J.M., et al. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J. Invest. Dermatol. 1997, 108:901-907.
6. McMillan J.R., Akiyama M., Shimizu H. Epidermal basement membrane zone components: ultrastructural distribution and molecular interactions. J. Dermatol. Sci. 2003, 31:169-177.
7. Giudice G.J., Emery D.J., Zelickson B.D., Anhalt G.J., Liu Z., Diaz L.A. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J. Immunol. 1993, 151:5742-5750.
8. Zillikens D., Rose P.A., Balding S.D., Liu Z., Olague-Marchan M., Diaz L.A., et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J. Invest. Dermatol. 1997, 109:573-579.
9. Tsuji-Abe Y., Akiyama M., Yamanaka Y., Kikuchi T., Sato-Matsumura K.C., Shimizu H. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J. Dermatol. Sci. 2005, 37:145-149.
10. Ujiie H., Shibaki A., Nishie W., Sawamura D., Wang G., Tateishi Y., et al. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J. Immunol. 2010, 184:2166-2174.
11. Budinger L., Borradori L., Yee C., Eming R., Ferencik S., Grosse-Wilde H., et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J. Clin. Invest. 1998, 102:2082-2089.
12. Lin M.S., Fu C.L., Giudice G.J., Olague-Marchan M., Lazaro A.M., Stastny P., et al. Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J. Invest. Dermatol. 2000, 115:955-961.
13. Thoma-Uszynski S., Uter W., Schwietzke S., Schuler G., Borradori L., Hertl M. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J. Immunol. 2006, 176:2015-2023.
14. Delgado J.C., Turbay D., Yunis E.J., Yunis J.J., Morton E.D., Bhol K., et al. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:8569-8571.
15. Aoki-Ota M., Tsunoda K., Ota T., Iwasaki T., Koyasu S., Amagai M., et al. A mouse model of pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice. Br. J. Dermatol. 2004, 151:346-354.
16. Sitaru A.G., Sesarman A., Mihai S., Chiriac M.T., Zillikens D., Hultman P., et al. T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita. J. Immunol. 2010, 184:1596-1603.
17. + T cells are essential to induce experimental autoimmune myasthenia gravis. J. Exp. Med. 1996, 184:349-356.
18. Noelle R.J., Roy M., Shepherd D.M., Stamenkovic I., Ledbetter J.A., Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:6550-6554.
19. Peters A.L., Stunz L.L., Bishop G.A. CD40 and autoimmunity: the dark side of a great activator. Semin. Immunol. 2009, 21:293-300.
20. Im S.H., Barchan D., Maiti P.K., Fuchs S., Souroujon M.C. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J. Immunol. 2001, 166:6893-6898.
21. Aoki-Ota M., Kinoshita M., Ota T., Tsunoda K., Iwasaki T., Tanaka S., et al. Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model. J. Invest. Dermatol. 2006, 126:105-113.
22. Ohyama M., Ota T., Aoki M., Tsunoda K., Harada R., Koyasu S., et al. Suppression of the immune response against exogenous desmoglein 3 in desmoglein 3 knockout mice: an implication for gene therapy. J. Invest. Dermatol. 2003, 120:610-615.
23. Olasz E.B., Roh J., Yee C.L., Arita K., Akiyama M., Shimizu H., et al. Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice. J. Invest. Dermatol. 2007, 127:2807-2817.
24. Amagai M., Tsunoda K., Suzuki H., Nishifuji K., Koyasu S., Nishikawa T. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J. Clin. Invest. 2000, 105:625-631.
25. Sitaru C., Mihai S., Otto C., Chiriac M.T., Hausser I., Dotterweich B., et al. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J. Clin. Invest. 2005, 115:870-878.
26. Lanschuetzer C.M., Olasz E.B., Lazarova Z., Yancey K.B. Transient anti-CD40L co-stimulation blockade prevents immune responses against human bullous pemphigoid antigen 2: implications for gene therapy. J. Invest. Dermatol. 2009, 129:1203-1207.
27. Howard L.M., Miga A.J., Vanderlugt C.L., Dal Canto M.C., Laman J.D., Noelle R.J., et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. 1999, 103:281-290.
28. Kalled S.L., Cutler A.H., Datta S.K., Thomas D.W. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J. Immunol. 1998, 160:2158-2165.
29. Quezada S.A., Eckert M., Adeyi O.A., Schned A.R., Noelle R.J., Burns C.M. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum. 2003, 48:2541-2554.
30. Di Zenzo G., Grosso F., Terracina M., Mariotti F., De Pita O., Owaribe K., et al. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J. Invest. Dermatol. 2004, 122:103-110.
31. Di Zenzo G., Thoma-Uszynski S., Fontao L., Calabresi V., Hofmann S.C., Hellmark T., et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin. Immunol. 2008, 128:415-426.
32. Di Zenzo G., Thoma-Uszynski S., Calabresi V., Fontao L., Hofmann S.C., Lacour J.P., et al. Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J. Invest. Dermatol. 2011, 131:2271-2280.
33. Di Zenzo G., Calabresi V., Olasz E.B., Zambruno G., Yancey K.B. Sequential intramolecular epitope spreading of humoral responses to human BPAG2 in a transgenic model. J. Invest. Dermatol. 2010, 130:1040-1047.
34. Li Q., Ujiie H., Shibaki A., Wang G., Moriuchi R., Qiao H.J., et al. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model. J. Immunol. 2010, 185:7746-7755.
35. Liu Z., Giudice G.J., Swartz S.J., Fairley J.A., Till G.O., Troy J.L., et al. The role of complement in experimental bullous pemphigoid. J. Clin. Invest. 1995, 95:1539-1544.
36. Wang G., Ujiie H., Shibaki A., Nishie W., Tateishi Y., Kikuchi K., et al. Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen. Am. J. Pathol. 2010, 176:914-925.
37. Iwata H., Kamio N., Aoyama Y., Yamamoto Y., Hirako Y., Owaribe K., et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J. Invest. Dermatol. 2009, 129:919-926.